Last updated: August 17, 2026
Primaquine phosphate is an old, low-cost antimalarial with no meaningful remaining composition-of-matter exclusivity in major markets. Its commercial value is driven by malaria-control programs, public procurement, availability of G6PD testing, and use in Plasmodium vivax radical cure and Plasmodium falciparum transmission reduction. The market has limited pricing power, fragmented suppliers, and low visibility into manufacturer-level revenue.
What is primaquine phosphate used for?
Primaquine phosphate is the phosphate salt of primaquine, an 8-aminoquinoline antimalarial. It is converted to primaquine base for dosing calculations and is used primarily for:
- Radical cure of Plasmodium vivax malaria by eliminating dormant liver hypnozoites.
- Radical cure of Plasmodium ovale malaria.
- Reduction of Plasmodium falciparum transmission through activity against gametocytes.
- Selected malaria-control and elimination programs under national or World Health Organization guidance.
In the United States, the FDA-approved product is generally supplied as 26.3 mg primaquine phosphate tablets, equivalent to 15 mg primaquine base per tablet. Treatment regimens vary by indication, patient weight, geography, and national guidelines. CDC guidance commonly uses a 14-day regimen for P. vivax or P. ovale radical cure, although shorter or weight-adjusted regimens may be used in specific settings.[1]
Primaquine causes clinically significant hemolysis in patients with glucose-6-phosphate dehydrogenase deficiency. G6PD testing is therefore a central commercial and regulatory requirement for broader deployment.
How large is the primaquine phosphate market?
No reliable public source reports a standalone global revenue figure for primaquine phosphate. The product is usually included within broader antimalarial procurement, hospital pharmacy, or national malaria-program budgets. Manufacturer revenue is also difficult to isolate because suppliers sell multiple antimalarial products through government tenders and international procurement agencies.
Market demand is structurally supported by the scale of malaria:
| Indicator |
Latest widely reported figure |
| Global malaria cases in 2023 |
Approximately 263 million |
| Global malaria deaths in 2023 |
Approximately 597,000 |
| Countries with ongoing malaria transmission |
Approximately 80 |
| Estimated global malaria funding in 2023 |
Approximately $4.1 billion |
| Main demand regions |
Sub-Saharan Africa, South and Southeast Asia, Latin America |
The World Health Organization reported a further increase in malaria cases in 2023 compared with 2022, while funding remained below the level required to meet global targets.[2] Primaquine demand does not track total malaria cases one-for-one because P. vivax is concentrated in regions where P. falciparum is less dominant, while the drug’s transmission-reduction role is expanding in elimination programs.
Principal demand drivers
The strongest demand drivers are:
- P. vivax radical-cure programs in Asia, Oceania, Latin America, and parts of the Horn of Africa.
- National malaria-elimination strategies requiring treatment of the liver stage.
- Use with artemisinin-based combination therapies in selected transmission-reduction programs.
- Expanded G6PD testing, including point-of-care testing.
- Government tenders and donor-funded procurement.
Demand is constrained by hemolysis risk, the need for G6PD assessment, adherence problems associated with a 14-day course, and the availability of tafenoquine in some markets.
What is the financial trajectory for primaquine phosphate?
Primaquine phosphate is a mature generic drug with a low-price, volume-dependent financial profile. Its financial trajectory is more likely to be stable or modestly growing in units than to show pharmaceutical-style revenue expansion.
| Financial factor |
Market effect |
| Generic status |
Suppresses price and gross-margin expansion |
| Public-sector procurement |
Creates volume but limits pricing power |
| Malaria burden |
Supports long-term demand |
| G6PD testing requirements |
Restricts use in poorly equipped settings |
| P. vivax elimination programs |
Provides targeted growth |
| Tafenoquine competition |
Pressures primaquine in selected radical-cure markets |
| Limited manufacturer disclosure |
Prevents reliable product-level revenue modeling |
A commercial model for primaquine phosphate should therefore focus on tablet volume, tender wins, geographic access, manufacturing cost, regulatory registrations, and supply continuity rather than branded prescription growth.
Revenue exposure by channel
Government and donor-funded procurement is likely to represent a substantial share of global demand. Private retail and hospital sales are more important in countries where malaria diagnosis and treatment are decentralized. The U.S. market is commercially small relative to the total malaria burden because malaria is mostly imported and primaquine use is concentrated in travel-related or specialist infectious-disease treatment.
The principal financial risks are:
- Tender price compression.
- Intermittent public-sector demand.
- Supplier exits caused by low margins.
- Country-specific registration requirements.
- Substitution by tafenoquine for suitable P. vivax patients.
- Procurement delays caused by changes in malaria policy or donor funding.
The principal upside is volume growth from expanded radical-cure coverage and greater adoption of G6PD testing.
When does primaquine phosphate lose exclusivity?
Primaquine phosphate lost practical exclusivity decades ago. The active ingredient was developed in the mid-20th century, well before modern pharmaceutical patent terms could support current commercial protection. The original composition-of-matter, formulation, and basic therapeutic-use rights are no longer commercially blocking.
The current U.S. product is a legacy generic medicine rather than a patent-protected branded asset. There is no credible exclusivity-based pricing mechanism comparable with a new chemical entity, a recently approved formulation, or a biologic.
Exclusivity timeline
| Event |
Commercial significance |
| Primaquine introduced in the 1950s |
Original discovery rights are long expired |
| Modern U.S. patent term applied to later filings |
Any such patents would generally have expired unless tied to later innovations |
| Generic tablet supply |
Established for many years |
| Current FDA market |
No meaningful new-drug exclusivity expected |
| Current commercial position |
Price competition and procurement access determine value |
What patents protect primaquine phosphate?
No active, commercially material patent estate is generally associated with the basic primaquine phosphate molecule or conventional immediate-release tablets. Any original compound patents and early therapeutic patents expired long ago.
Potentially relevant patent categories would include:
- New dosage regimens.
- Modified-release formulations.
- Combination treatments.
- G6PD-guided dosing systems.
- Diagnostic-treatment combinations.
- Manufacturing processes.
- New salts or crystalline forms.
- Pediatric delivery systems.
These categories could support narrow patent rights if a company developed a genuinely novel product. They would not ordinarily restore exclusivity to standard primaquine phosphate tablets.
How strong is the patent estate for primaquine phosphate?
The patent estate for the conventional product is weak. A standard tablet manufacturer is unlikely to face a meaningful patent barrier based solely on selling primaquine phosphate in an immediate-release dosage form.
Patent strength is higher for a differentiated product that combines:
- A novel dosing schedule.
- A validated low-dose regimen for deficient or intermediate G6PD populations.
- A proprietary formulation improving adherence.
- A protected diagnostic and treatment workflow.
- A new combination with another antimalarial.
Even in those categories, enforceability and commercial value depend on claim scope, clinical evidence, regulatory approval, and the ability to distinguish the product from public-health guidelines.
What is the Orange Book status of primaquine phosphate?
The FDA Orange Book is relevant to approved U.S. drug products and listed patents. Primaquine phosphate is not generally regarded as an Orange Book-protected product with active patent exclusivity. Conventional generic suppliers therefore do not face the type of listed-patent risk associated with newer branded drugs.
The practical U.S. regulatory position is:
| Issue |
Primaquine phosphate |
| FDA status |
Approved prescription antimalarial product |
| Product type |
Small-molecule generic or legacy approved product |
| New chemical entity exclusivity |
Expired |
| Pediatric exclusivity |
No commercially material current exclusivity expected |
| Orphan exclusivity |
Not a principal market feature |
| Active composition patent |
No practical barrier |
| Orange Book litigation exposure |
Low for the standard product |
Orange Book analysis should still be conducted at the product and NDA level because patent listings can vary by sponsor and formulation. The strategic conclusion remains unchanged: standard primaquine phosphate is not protected by a modern, high-value Orange Book patent position.[3]
Are there Paragraph IV challenges involving primaquine phosphate?
Paragraph IV litigation risk is low. A Paragraph IV certification is most relevant when an ANDA applicant seeks approval before expiration of an Orange Book-listed patent. Primaquine phosphate’s basic active ingredient and conventional tablet form are old, and there is no well-established active patent thicket comparable with drugs such as lenalidomide, inhaled respiratory products, or long-acting injectables.
Potential Paragraph IV activity could arise only if a sponsor listed a later patent covering a specific formulation, method of use, or manufacturing process. Such litigation would likely concern the narrow improvement rather than primaquine phosphate itself.
Generic launch scenarios
| Scenario |
Likely outcome |
| Additional standard-tablet ANDA |
Rapid approval is possible if product and regulatory requirements are met |
| Launch after patent review |
Low delay risk for the conventional tablet |
| Paragraph IV challenge to a narrow formulation |
Possible litigation, but limited to the patented feature |
| Government-tender entry |
Commercially more important than patent litigation |
| Launch in malaria-endemic markets |
Registration, local supply, and procurement qualification are decisive |
What formulations are protected by primaquine phosphate patents?
The standard immediate-release tablet has little defensible patent value. The main opportunities for formulation protection would be:
- Pediatric dispersible tablets.
- Taste-masked formulations.
- Fixed-dose combinations.
- Modified-release products intended to improve adherence.
- Lower-dose products designed around G6PD risk management.
- Heat- and humidity-stable tablets for tropical supply chains.
- Point-of-care co-packaged diagnostic and treatment products.
A formulation patent would need to provide a measurable technical advantage. A simple change in tablet size, excipient, packaging, or dose strength may be vulnerable to obviousness challenges unless supported by unexpected performance data.
What method-of-use patents cover primaquine phosphate?
The strongest potential method-of-use claims concern:
- Radical cure of P. vivax or P. ovale.
- Gametocyte clearance in P. falciparum infection.
- Dosing based on quantitative G6PD activity.
- Shortened or intermittent treatment regimens.
- Use with a specific companion antimalarial.
- Treatment of defined patient populations or geographic parasite strains.
The basic use of primaquine for radical cure is old and does not provide meaningful new exclusivity. A later method patent could still have value if it claims a clinically validated regimen that differs materially from established practice. Its market value would be limited if physicians can achieve the same result with an unpatented regimen.
How does primaquine compare with tafenoquine?
Tafenoquine is the most relevant branded or differentiated competitive alternative for P. vivax radical cure. Both drugs are 8-aminoquinolines, but tafenoquine has a substantially longer half-life and can support a shorter treatment regimen.
| Attribute |
Primaquine phosphate |
Tafenoquine |
| Drug class |
8-aminoquinoline |
8-aminoquinoline |
| Main role |
Radical cure and transmission reduction |
P. vivax radical cure |
| Typical treatment burden |
Often 7 to 14 days |
Single-dose or shorter regimen, depending on product and jurisdiction |
| Price position |
Low-cost generic |
Higher-cost differentiated product |
| G6PD requirement |
Important |
Important and generally more restrictive because of long exposure |
| Adherence |
Daily-course challenge |
Better dosing convenience |
| Supplier landscape |
Broad and fragmented |
More concentrated |
| Patent position |
Mature, largely unprotected |
Later-product patents and regulatory protections may apply |
Primaquine retains advantages in cost, global familiarity, and availability. Tafenoquine has advantages in adherence and regimen simplicity. The competitive balance depends on the price of G6PD testing, local regulatory approvals, clinical protocols, and procurement budgets.[4]
What biosimilar risk exists for primaquine phosphate?
There is no biosimilar risk. Primaquine phosphate is a small-molecule chemical drug, not a biologic. Competitive entry occurs through generic-drug pathways, including ANDAs in the United States and corresponding national procedures elsewhere.
The relevant competitive risks are generic substitution, supply-side price competition, tafenoquine adoption, and development of other radical-cure regimens.
Which companies manufacture or supply primaquine phosphate?
Supply is fragmented and varies by country. Products may be manufactured by generic pharmaceutical companies, regional suppliers, government-linked manufacturers, and contract manufacturers. The commercial landscape can change when companies discontinue low-margin products or fail to renew national registrations.
In the United States, product availability has historically been affected by manufacturer changes and intermittent supply conditions. The FDA Drug Shortages database and DailyMed are more reliable indicators of current availability than historical market-share information.[5][6]
The most relevant competitive capabilities are:
- FDA or other stringent-regulatory-authority approval.
- WHO procurement eligibility where applicable.
- Stable active pharmaceutical ingredient supply.
- Tropical-stability packaging.
- Ability to meet government tender specifications.
- Multi-country registrations.
- Reliable quality-control documentation.
What manufacturing and intellectual-property barriers exist?
Manufacturing barriers are moderate rather than patent-driven. Primaquine phosphate is a small-molecule product with an established synthesis, but commercial production still requires validated control of impurities, assay, dissolution, stability, and tablet uniformity.
Key barriers include:
- Qualified primaquine API suppliers.
- Compliance with current good manufacturing practices.
- Validation of impurity and degradation-product controls.
- Stability under high temperature and humidity.
- Bioequivalence or comparative quality requirements.
- Country-specific packaging and serialization rules.
- Procurement qualification and quality audits.
The API itself is not likely to be the primary source of competitive advantage. Supply reliability and regulatory execution are more important.
What litigation and settlement agreements affect primaquine phosphate?
There is no widely recognized, material U.S. patent-litigation or settlement landscape surrounding conventional primaquine phosphate tablets. The absence of major litigation is consistent with the product’s age, generic status, and limited patent value.
Any future dispute would more likely involve:
- A later formulation patent.
- A combination product.
- A diagnostic-linked dosing method.
- Manufacturing-process rights.
- Contract, supply, or quality disputes.
This differs from markets where branded drug sponsors use multiple listed patents and settlements to delay ANDA entry.
What is the FDA regulatory status of primaquine phosphate?
Primaquine phosphate is an FDA-approved prescription antimalarial. Its use is governed by labeling and public-health guidance concerning:
- G6PD deficiency.
- Hemolytic anemia.
- Methemoglobinemia.
- Pregnancy.
- Breastfeeding.
- Concomitant exposure to other hemolysis-inducing drugs.
- Pediatric dosing and weight-based administration.
FDA labeling states that primaquine is contraindicated in patients with severe G6PD deficiency and in pregnancy unless the G6PD status of the fetus can be established as normal.[7] The regulatory requirement for patient selection remains a central constraint on adoption.
What generic entry risks exist?
For a standard primaquine phosphate tablet, generic entry risk is already realized rather than prospective. The product has a mature generic market and lacks a credible patent-based delay mechanism.
The main commercial risks are:
- New entrants undercutting tender prices.
- Contract manufacturers entering through low-cost supply.
- Regional suppliers obtaining preferential government access.
- Buyers shifting to tafenoquine where adherence has higher value.
- National programs reducing primaquine use because G6PD infrastructure is inadequate.
- Product discontinuation by suppliers when volumes do not support manufacturing economics.
For a differentiated product, the risk changes. A new formulation could face rapid generic substitution after any patent expiry, while a diagnostic-linked product could face competition from non-pharmaceutical approaches to improving radical-cure access.
What is the geographic coverage of primaquine phosphate?
Primaquine is used across a wide geographic range, but demand is concentrated in countries with P. vivax transmission and malaria-elimination programs.
Highest-value geographic regions
- India and neighboring South Asian markets.
- Indonesia and parts of Southeast Asia.
- Papua New Guinea and the Western Pacific.
- Brazil and other Latin American countries.
- Afghanistan and parts of Central Asia.
- Selected African countries where P. vivax or mixed transmission occurs.
- The United States, Europe, and Australia for imported-malaria treatment.
Regulatory strategy should prioritize countries where primaquine is included in national malaria guidelines and where G6PD testing is available or being introduced. A registration alone does not ensure commercial demand because procurement is often centralized.
Key Takeaways
- Primaquine phosphate is a mature generic antimalarial with no meaningful remaining composition-of-matter exclusivity.
- The standard tablet has low patent strength and low expected Orange Book litigation risk.
- No biosimilar risk exists because primaquine is a small-molecule drug.
- Financial performance depends on public procurement, malaria-elimination programs, and supply reliability.
- P. vivax radical cure is the principal growth opportunity.
- Tafenoquine is the most important differentiated competitor because of its shorter treatment regimen.
- G6PD testing is both a safety requirement and a market-enabling technology.
- Product-level revenue is not publicly disclosed in a reliable standalone form.
- Formulation, dosing, diagnostic-linked, and combination patents are the only plausible areas for new intellectual-property value.
- Generic entry is already established; future competition will center on price, quality, geographic registrations, and procurement access.
FAQs About Primaquine Phosphate
Is primaquine phosphate still commercially attractive?
It is commercially attractive as a high-volume, low-margin public-health product, not as a premium branded medicine. The best opportunities are in stable government procurement and differentiated formulations.
Can primaquine phosphate be sold without G6PD testing?
Clinical requirements vary by jurisdiction and regimen, but G6PD status is central to safe use. Severe G6PD deficiency creates a material hemolysis risk, and regulatory labeling restricts use in affected patients.
Is primaquine phosphate protected by a patent in the United States?
The conventional active ingredient and immediate-release tablet are not protected by a commercially meaningful current patent estate. Later patents could cover a specific formulation, regimen, or combination.
Does tafenoquine replace primaquine phosphate?
No. Tafenoquine competes with primaquine for P. vivax radical cure, but primaquine remains important because it is inexpensive, familiar, and available across more markets.
What would increase the value of a primaquine phosphate product?
A pediatric formulation, improved adherence profile, heat-stable presentation, validated G6PD-guided dosing system, or fixed-dose combination could increase value. Commercial success would still depend on national guideline inclusion and procurement access.
References
-
Centers for Disease Control and Prevention. (2024). Malaria: Treatment tables and guidance. https://www.cdc.gov/malaria/hcp/clinical-guidance/
-
World Health Organization. (2024). World malaria report 2024. https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2024
-
U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (2018). Arakoda and Krintafel prescribing information. https://www.accessdata.fda.gov/
-
U.S. Food and Drug Administration. (2025). Drug shortages. https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages
-
U.S. National Library of Medicine. (2025). DailyMed: Primaquine phosphate. https://dailymed.nlm.nih.gov/dailymed/
-
U.S. Food and Drug Administration. (2023). Primaquine phosphate tablets prescribing information. https://www.accessdata.fda.gov/
